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↑What is “already known” in this topic: 
• Mild cognitive impairment in PD (PD-MCI) is found in over 
a quarter of patients, may be present at diagnosis and is 
predictive of the risk of developing dementia. 
• The Montreal Cognitive Assessment (MoCA) has been 
recommended as a cognitive screening tool for clinical practice 
and research in PD.   
 
→What this article adds: 
• We present the normative data for MoCA in people with PD 
without clinical dementia.  
• Age appeared to be the only associated factor for lower level 
of cognition suggestive of PD-MCI in PD without clinical 
diagnosis of dementia.  
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Abstract 
    Background: The Montreal Cognitive Assessment (MoCA) has been recommended as a cognitive screening tool for clinical 
practice and research in Parkinson’s disease (PD), yet no normative data have been published for MoCA in PD without dementia.   
   Methods: We undertook a pooled secondary analysis of data from two studies (one cross-sectional design and one clinical trial) 
conducted in the East of England region. All participants were aged 18 years or over, met UK Brain Bank criteria for PD and did not 
have clinical dementia. Cognitive status was assessed using MoCA at baseline in both studies. The influences of age, gender, disease 
duration, medication load (LEDD) and mood (HADS) on cognition were examined using regression analysis. 
   Results: Data from 101 people with PD without dementia were available (mean age 71 years, 66% men). Median (IQR) MoCA was 
25(22, 27). Age was found as the only predictor of MoCA in this sample. People aged over 71 had poorer MoCA (Beta=0.6 (95%CI 
0.44, 0.82)) and an increased odds of MoCA <26 (Beta=0.29 (95%CI 0.12, 0.70)) as well as poorer scores on several MoCA sub-
domains.  
   Conclusion: We present the normative data for MoCA in people with PD without clinical dementia. Age appeared to be the only 
associated factor for lower level of cognition, suggestive of Mild cognitive impairment in PD (PD-MCI) in PD without clinical 
diagnosis of dementia. 
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Introduction 
Parkinson’s disease (PD) is a common neurodegen-
erative condition affecting around 1.5% of people over 
65 in Europe (1). Mild cognitive impairment in PD 
(PD-MCI) is found in over a quarter of patients (2), 
may be present at diagnosis (3) and is predictive of the 
risk of developing dementia (2), an outcome that oc-
curs in over 80% of patients (4). 
There exist a range of tools that can be used to as-
sess cognitive status in PD. However, long-established 
assessment tools such as the Mini Mental State Exam-
ination (MMSE) (5) have been shown to be insensitive 
to mild cognitive impairment in PD (6). The Montreal 
Cognitive Assessment (MoCA) (7) is a brief screening 
tool that, based on its good psychometric properties, 
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has been recommended for clinical practice and re-
search (8) and approved by the Movement Disorder 
Society for the Level 1 criteria for PD-MCI diagnosis 
(9). 
The potential advantages of MoCA over more tradi-
tional cognitive diagnostic tools such as MMSE have 
been studied for a considerable period of time. For ex-
ample, Mamikonyan et al (6) found that MoCA de-
tected mild cognitive impairment in 29% of people 
with PD with normal age- and education-adjusted 
MMSE scores.  Hoops et al (10), Zadikoff et al (11), 
and Dalrymple-Alford et al (12) all also found MoCA 
to be superior to MMSE in detecting mild cognitive 
impairment in PD. Moreover, Biundo et al (13) found 
MoCA to be superior to MMSE in assessing cognitive 
change.  
However, the focus has been largely on psychomet-
rics rather than epidemiological investigation. Alt-
hough normative data for PD with dementia have been 
published in the Greek setting (14), there were only 19 
participants in the study. Moreover, to our knowledge, 
no normative data for MoCA in people with PD with-
out dementia have been previously reported, with ex-
isting studies instead focusing on assessing parameters 
such as test-retest reliability or convergent validity 
compared to other test instruments. Normative data 
would be useful for future research and practice. In 
addition to a lack of normative data for MoCA in peo-
ple with PD without dementia, the pathophysiology of 
PD-MCI remains poorly understood (15) and the con-
tribution of clinical and demographic risk factors for 
cognitive impairment in PD remains unestablished. 
One study has assessed the sensitivity and specificity 
of the domain-specific subsections of MoCA (16). 
Given the lack of identified MoCA-specific norma-
tive data for people with PD without dementia, and the 
advantages such descriptive epidemiological data 
would offer in terms of guiding further research and 
better understanding cognitive impairment in PD and 
how this recommended tool can profile it, we under-
took the analyses presented in this article.  The aims of 
the study, therefore, are to i) present normative data 
for MoCA in people with PD without dementia; ii) as-
sess the associations with potential risk factors for PD-
MCI as measured by MoCA score. 
 
Methods 
Design and data sources 
This article presents a pooled secondary analysis of 
de-duplicated anonymised data from two studies (17, 
18) conducted in the East of England region. One was 
a cross-sectional observational study of functional 
communication in PD (17), while the other was a pilot 
randomised controlled trial of adherence therapy to 
improve medication adherence and quality of life in 
PD (18). These studies received Ethics approval from 
the National Research Ethics Service East of England 
Cambridge Central and Norfolk committees, respec-
tively. 
 
Eligibility criteria 
In order to be eligible for this analysis, participants 
had to: be aged 18 years or over, have a diagnosis of 
PD according to the UK Brain Bank Criteria (19), and 
have no clinical indication of dementia. Additionally, 
due to the specific requirements all participants in the 
study by Barnish et al (17) had to: have some degree 
of self-reported speech or communication difficulty, 
and have no history of other serious medical condi-
tions likely to affect cognition, speech or communica-
tion. All participants from Daley et al (18) had to: be 
prescribed one or more antiparkinsonian medications, 
be on a stable medication regime, and have a Morisky 
Medication Adherence Score (20) of at least 1. 
 
Measures 
Cognitive status was assessed using MoCA (7) in 
both studies at the time of study enrolment. Scores for 
MoCA subsections were also collected. Medication 
load was assessed using Levodopa Equivalent Daily 
Dose (LEDD) (21). Anxiety and depression were as-
sessed using the Hospital Anxiety and Depression 
Scale (HADS) (22). Age, gender and disease duration 
in years were also extracted from the respective study 
databases. 
MoCA has been shown in a Parkinson Study Group 
(PSG) Cognitive/Psychiatric Working Group task 
force systematic review (8) to be feasible to administer 
in a PD context, able to stand alone as a brief cognitive 
assessment taking <15 minutes, assess all the major 
cognitive domains, be able to identify subtle cognitive 
impairment and have PD-specific psychometric data 
showing good test-retest reliability, inter-rater reliabil-
ity and convergent validity across studies, have good 
sensitivity, some limitations in terms of specificity, 
and be able to identify mild cognitive impairment not 
detected by the MMSE. LEDD is an algorithm that 
was validated in a PD context through a systematic re-
view (7) which provided the evidence base to derive 
the LEDD formulae. HADS is recommended as both a 
depression and an anxiety scale in PD according to 
Movement Disorder Society (MDS) task force system-
atic reviews (23-24). For depression, HADS was 
found across studies to have good internal consistency 
and test re-test reliability, acceptable sensitivity with 
some limitations in terms of specificity, it contained 
>50% psychological items, and benefitted from having 
<25% somatic items, resulting in little overlap with 
non-depressive symptoms of PD (23). For anxiety, 
HADS was found across studies to have satisfactory 
internal consistency and test-retest reliability, and to 
have a fair to moderate correlation with quality of life 
measures, but be unable to discriminate between anxi-
ety and depression in PD (24). Therefore, we did not 
use HADS to measure anxiety and depression as sepa-
rate constructs.  
 
Statistical analysis 
Statistical analysis was conducted using STATA 
software (25). Descriptive statistics were used to pro-
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file age, gender, disease duration, LEDD, HADS total 
score, MoCA total score and MoCA subsection scores 
(visuospatial, naming, attention, language, abstraction, 
delayed recall and orientation) using n (%), mean (SD) 
and median (IQR) as appropriate. MoCA total score 
was also profiled according to these potential risk fac-
tors for poor cognition. Then, regression models were 
constructed to assess the relationship between the fol-
lowing potential predictors: age, using median age of 
the cohort as a categorical cut off point (age 72 or over 
vs age 71 or below), gender, disease duration, HADS 
(<15 vs. >=15), quartiles of LEDD and MoCA score 
and MoCA subsection scores. 
Full case analysis was used with logistic transfor-
mation applied. Relationships with the naming sub-
scale could not be assessed due to insufficient varia-
tion in outcome scores. 
 
Results 
A total of one hundred and one participants with PD 
were included in this study. The dataset from Barnish 
et al (17) provided 45 participants, while the dataset 
from Daley et al (18) provided an additional 56 partic-
ipants. Twenty people participated in both studies and 
are therefore counted only once. The mean age (SD) of 
included participants was 71.3±8.8 years. Sixty-seven 
participants (66%) were men and the median disease 
duration was 8.0 years (IQR 4.0 to 13.0). The median 
LEDD score was 660.6 units (IQR 444.8 to 1109.4). 
The mean (SD) total HADS score was 10.3 (±5.7). 
Descriptive scores for total MoCA, potential risk 
factors of interest and the individual subsections of 
MoCA are provided in Table 1. The distribution of to-
tal MoCA scores is shown in Figure 1. The median 
value was 25 (IQR 22, 27), which is indicative of cog-
nitive impairment in at least 50% of people with PD 
without apparent dementia. Sex-specific analysis 
showed (Fig. 2) that the cognitive profiles are compa-
rable between men (mean 24.3, 95% CI 23.3, 25.4) 
and women (mean 24.6, 95% CI 23.4, 25.8). Similarly, 
MoCA scores did not differ substantially as a function 
of LEDD, HADS or disease duration. 
Nevertheless, older participants had consistently 
lower MoCA scores (Fig. 3). For example, among par-
ticipants in the 45-54 years age category, the mean 
(95% CI) MoCA score was 28.0 (26.2, 29.8), whereas 
among over 75s, it was 23.1 (21.5, 24.7) 
In inferential regression analysis, older age was a 
significant predictor of lower MoCA total score (Be-
ta= 0.6, 95% CI 0.44, 0.82, p<0.001 for age below 
median vs age above median). Older age is associated 
with greater odds of cognitive impairment defined as a 
MoCA score<=26 (OR=3.45, CI: 1.43, 8.33, p=0.006), 
indicating cognitive impairment. Gender, disease dura-
tion, HADS score and LEDD score did not significant-
ly predict MoCA total score or the odds of a MoCA 
score <=26. With regard to MoCA subscales, older age 
was a significant predictor of lower scores on the de-
layed recall (Beta=0.29, 95%CI:  0.11, 0.78, p=0.014), 
attention (Beta=0.44, CI: 0.2, 0.99, p=0.046) and 
Table 1. Descriptive profile of MoCA total, risk factors and subsection scores 
Measure Mean; SD Median; IQR N; % 
Age 71.3 (8.8) - - 
Gender (male) - - 67; 66.3 
Disease duration (years) - - 8.0; 4.0-13.0 
LEDD - 660.6; 444.8-1109.4 - 
HADS total 10.3 (5.7) - - 
MoCA total - 25.0; 22.0-27.0 - 
MoCA visuospatial - 4.0; 3.0-5.0 - 
MoCA naming - 3.0; 3.0-3.0 - 
MoCA attention - 6.0; 5.0-6.0 - 
MoCA language - 3.0; 2.0-3.0 - 
MoCA abstraction - 2.0; 2.0-2.0 - 
MoCA delayed recall - 3.0; 2.0-4.0 - 
MoCA orientation - 6.0; 6.0-6.0 - 
The most appropriate type of value is shown here for each outcome 
 
 
Fig. 1. Distribution of MoCA scores 
 
 
Fig. 2. Distribution of MoCA subdivided by gender 
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visuospatial function (Beta=0.34, 95% CI: 0.15,0.78, 
p=0.010) subscales. 
 
Discussion 
To our knowledge this is the first study to present 
normative data for MoCA in people with PD without 
clinical dementia and to present associations between 
potential risk factors and MoCA score as the proxy 
marker of PD-MCI in this population. We found that 
more than half of participants with PD have cognitive 
impairment according to MoCA despite no overt de-
mentia. Our study benefited from the use of MoCA as 
a sensitive indicator of PD-MCI as suggested by the 
literature in this field (8, 10-12). 
We also present a graphical depiction of the distribu-
tion of MoCA scores to better understand the descrip-
tive epidemiology of cognition in the context of PD 
without clinical dementia. We provide descriptive in-
formation for the different domains of MoCA, alt-
hough no cut-off scores are available for the MoCA 
domains, unlike the MoCA total score. However, our 
results are suggestive of impairment across a broad 
range of cognitive areas, and are broadly congruent 
with the results of a recent meta-analysis (not MoCA-
specific) in this respect (26). We found no gender dif-
ferences in cognitive profile of people with PD across 
wide range of people with PD. Of our potential risk 
factors for PD-MCI, we only found a statistically sig-
nificant association with age. In particular, we found 
that older people had poorer total MoCA scores. They 
also had poorer scores on the delayed recall, attention 
and visuospatial subscales, as well as an increased 
likelihood of having a total MoCA score lower than 
26, which indicates cognitive impairment. This sug-
gest that factors such as LEDD and disease duration 
may be less important for predicting the onset of cog-
nitive decline in PD, and that age should be specifical-
ly acknowledged when planning potential interven-
tions targeting cognition. Whether age in addition to 
disease duration, or other potential risk factors, further 
helps predict cognitive decline remains unknown and 
represents an area of further investigation. 
Our study has several strengths. Through pooling 
two studies that specifically excluded people with clin-
ical dementia, we were able to present the first norma-
tive data for people with PD exclusively without ap-
parent clinical dementia. Moreover, pooling these 
studies that shared a number of key clinical measures 
allowed us to study a sample size over five times larg-
er than a prior study that provided some initial MoCA 
data in PD with dementia (14). 
There are also some limitations we should consider. 
This is a secondary analysis, meaning that the sample 
size was powered on the objectives of the primary 
studies and the data available depend on what these 
studies collected. Therefore, regression analysis may 
be underpowered and has potential for missing possi-
ble associations. Also, this is a single- centre study 
with both primary studies having recruited from the 
same large academic medical centre in the East of 
England region with an overrepresentation of Cauca-
sian individuals. 
Future studies should seek to confirm the cognitive 
profile we present for people with PD without demen-
tia, conduct further assessment of risk factors for PD-
MCI using MoCA, assess prognosis and also consider 
the role of social factors such as keeping mentally and 
physically active. Such a programme of research could 
enable consideration of how cognitive risk scores 
could be calculated and used, as well as how to poten-
tially slow or avoid cognitive decline in PD. The cog-
nitive profile we present here could be an important 
foundation for this future research. In turn, such re-
search could assess whether cognitive assessment for 
PD should be integrated into routine clinical practice 
and what benefits this might bring for patient out-
comes. 
 
Conclusion 
We present an analysis and graphical profile of 
MoCA scores in people with PD without dementia. 
More than half of participants had MoCA scores indi-
cating cognitive impairment despite no overt demen-
tia. Age predicted MoCA score, although no other var-
iables were found to be predictive. Older people had 
poorer MoCA scores and were more likely to have a 
total MoCA score lower than 26 indicating cognitive 
impairment.  
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